CompletedNCT05458479
Fluoxetine safety and effects for depression in adults with Down syndrome
About this title
Read the official source — NCT05458479Medication studyAges 18–45United States
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
What did participation involve?
The study group receives fluoxetine as a study medication.
- Listed locations
- LexingtonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: December 5, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 4
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 45 Years
- Official registry ID
- NCT05458479
- Official title
Show the full official title
Fluoxetine Treatment of Depression in Adults With Down Syndrome
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Lexington
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Fluoxetine.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.
